On May 23, 2022 Modra Pharmaceuticals ("Modra") reported that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO (Free ASCO Whitepaper) General Annual Meeting held from June 3 – 7, 2022 virtually and in-person in Chicago, IL, USA (Press release, Modra Pharmaceuticals, MAY 23, 2022, View Source [SID1234615952]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please see below for details on the poster abstract.

Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Poster Title: A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Ulka N. Vaishampayan, MD | University of Michigan
Location: In-Person & Live Stream | Arie Crown Theater
Session Date and Time: June 6, 2022 from 16:30 CDT – 18:00 CDT
Abstract Number: 5016
Poster Number: 200

About metastatic Castration-Resistant Prostate Cancer (mCRPC)

mCRPC is an advanced form of prostate cancer and the fourth most common cause of cancer death overall. mCRPC is not amenable to surgical treatment and resistant to androgen deprivation therapy, a hormone therapy used as initial disease management to reduce growth of prostate cancer cells.

About ModraDoc006/r

ModraDoc006/r is a proprietary boosted taxane therapy based on docetaxel, an intravenously administered therapy, that is very broadly used in a variety of tumor types. ModraDoc006 – an oral docetaxel tablet – is given in combination with ritonavir (r), which acts as a booster to increase the systemic bioavailability of ModraDoc006. ModraDoc006/r is designed to combine the convenience and practicality of taking chemotherapy treatment at home with the potential for an improved safety profile, as compared to standard IV docetaxel.

On May 23, 2022 Chia Tai‑Tianqing Pharma (CTTQ), a Nanjing subsidiary of Sino Biopharma, reported that it will acquire global rights to an anti-LAG3 mAb from Symphogen A/S of Denmark (Press release, ChinaBio, MAY 23, 2022, View Source [SID1234615011]). Sym022 is a mAb that binds LAG3 to block the interaction with MHCII, which increases T cell proliferation and production of cytokines . In two Phase I trials, Sym022 proved itself to be safe and well-tolerated as a monotherapy and in combination with checkpoint inhibitors. Financial details of the transaction were not disclosed. Symphogen is the Antibody Center of Excellence for Servier, a privately held French biopharma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 23, 2022 (the "Effective Date"), CASI Pharmaceuticals, Inc. ("CASI") reported that entered into a Business Loan Agreement, Commercial Security Agreement, Commercial Pledge Agreement and a Promissory Note (collectively, the " Agreement") with East West Bank ("EWB") (Filing, 8-K, CASI Pharmaceuticals, MAY 23, 2022, View Source [SID1234614975]). Under the Agreement, EWB made available to the Company a revolving line of credit up to a maximum of USD $10.0 million. The Agreement contains customary representations, warranties, financial covenants and ratios, reporting and other covenants, and events of default. The Agreement will mature on December 31, 2022, unless extended to April 30, 2024 subject to certain conditions as defined in the Agreement. Proceeds received under the Agreement are intended to finance short-term working capital needs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In general, amounts borrowed under the Agreement are secured by a lien on the Company’s assets, including first priority security interest in accounts receivable and inventory and pledge of available-for-sale securities. Under the Agreement, CASI shall maintain at least $2,500,000 cash on deposit at EWB. EWB shall, when certain conditions are met, partially or fully release this cash deposit requirement.

Upon the Effective Date, the Company was required to pay a closing fee equal to $50,000. Amounts borrowed under the Agreement bear interest, payable monthly. Such interest shall accrue based upon the daily Wall Street Journal Prime Rate (as quoted in the "Money Rates" column of The Wall Street Journal (Western Edition)) plus 0.35 % with a floor rate of 3.85%. Interest is calculated by applying the ratio of the interest rate over a year of 360 days, multiplied by the outstanding principal balance, multiplied by the actual number of days the principal balance is outstanding.

The foregoing description of the Agreement does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the full text of the Agreement that will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

On May 23, 2022 Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported it will be presenting at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, a conference taking place in Chicago, IL from June 3 to 7, 2022 (Press release, Biomica, MAY 23, 2022, View Source [SID1234614965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ASCO (Free ASCO Whitepaper) (American Society of Clinical Oncology) Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. Biomica’s abstract, entitled "A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors," was selected for a poster and presentation session at the conference.

Furthermore, the poster has also been selected for the 2022 GRASP Advocate Choice Award. GRASP, which stands for Guiding Researchers and Advocates to Scientific Partnerships, and is a patient-led organization that brings together patients, clinicians, and researchers to exchange ideas and learn from each other to accelerate scientific breakthroughs. This is the third year ASCO (Free ASCO Whitepaper) is collaborating with GRASP, and this event will take place in parallel with the conference.

Dr. Corinne Maurice-Dror, Biomica’s Clinical Oncology advisor, will be presenting on Sunday, June 5, 2022 between 8am and 11am CDT.

Furthermore, Dr. Maurice Dror and Dr. Elran Haber, CEO of Biomica will be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.

On May 23, 2022 KaliVir Immunotherapeutics, Inc. reported a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir’s oncolytic immunotherapy VETTM platform (Press release, KaliVir Immunotherapeutics, MAY 23, 2022, View Source [SID1234614964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KaliVir will work with Roche to leverage KaliVir’s proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates. KaliVir’s VETTM platform can enhance the vaccinia viral backbone with a combination of proprietary genetic modifications to maximize tumor killing and systemic delivery and spread, and can be readily optimized to combine with a wide variety of therapeutic transgenes.

Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company’s VETTM platform expressing Roche proprietary therapeutic transgenes. Roche will have exclusive license to discover, develop and commercialize the products worldwide. KaliVir will receive an upfront payment, and may be eligible to receive research, development and commercial milestone payments, as well as tiered royalties on commercial sales of products emerging from the collaboration.

"We are extremely excited to work with Roche and its excellent scientific team to identify and develop novel, innovative treatments for cancer patients worldwide," said KaliVir CEO Helena Chaye. "Our VETTM platform is a powerful engine for identifying novel, innovative oncolytic immunotherapies, and we look forward to further expanding its potential and our broader discovery research capabilities through this discovery collaboration."

"Roche has been discovering and developing breakthrough treatments in oncology for more than 50 years. Building on our strong internal pipeline, we are continually looking for partnerships to foster the discovery and development of innovation to fundamentally change how we deliver care for patients now and in the future," stated James Sabry, Global Head of Pharma Partnering at Roche. "KaliVir and its promising VETTM platform represent an excellent example of exciting, cutting-edge technologies that we believe could make a difference for cancer patients."